

PRESS RELEASE

NEVA SGR: INTESA SANPAOLO INVESTS IN NUCLIDIUM'S NEXT-GENERATION CANCER RADIOPHARMACEUTICALS

- **With this new investment, NUCLIDIUM will develop its innovative copper-based proprietary radiotheranostic platform, which provides a combined approach to cancer diagnosis and treatment.**
- **Mario Costantini: *"NUCLIDIUM has the potential to profoundly innovate precision oncology and change the way radiotherapy care is delivered. We look forward to contributing to its growth and fostering collaboration with clinical facilities, research centres, and Italian companies in the industry."***
- **Leila Jaafar: *"Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care delivery and waste management, making these therapies more accessible worldwide."***

Turin, 18 July 2025 - **Neva SGR**, the **Intesa Sanpaolo Group's** venture capital company, a full subsidiary of **Intesa Sanpaolo Innovation Center**, has participated in a CHF 79 million (€84 million) funding round for **NUCLIDIUM**, a Swiss-German biotechnology company specialising in next-generation radiopharmaceuticals for cancer.

The new investment will enable **NUCLIDIUM** to accelerate the development of its innovative proprietary theranostic platform, which provides a combined approach to cancer diagnosis and treatment. **NUCLIDIUM** links tumour-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics. The precise targeting enables a more accurate diagnosis or treatment and reduces damage to healthy tissue.

NUCLIDIUM is preparing to expand its worldwide production network, grow its international team, and strengthen strategic collaborations with hospitals and academic centres, initially across Europe and North America.

The platform realised by **NUCLIDIUM** overcomes the current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. Diagnostic results from initial clinical trials in these indications show superior lesion detection and higher tumour-to-background ratios (tumour masses better visualized than adjacent healthy tissue), compared with clinically approved tracers, with a favourable safety profile. Early therapeutic data from the company's two lead

compounds, NuriPro and TraceNET, show strong tumour-to-background ratios in metastatic prostate cancer and neuroendocrine tumours, including breast cancer.

*"The investment in **NUCLIDIUM** confirms our commitment to selecting high-growth companies globally, with revolutionary patents and projects in the pipeline that can be applied on a large scale in the future, contributing to the solution of the planet's grand challenges, including the fight against cancer," says **Mario Costantini, CEO and General Manager of Neva SGR**. "**NUCLIDIUM** has the potential to profoundly innovate precision oncology and change the way radiotherapy care is delivered. We look forward to contributing to its growth and fostering collaboration with Italian clinical facilities, research centres and companies in the industry."*

*"With the support from a strong European syndicate, including Neva SGR, **NUCLIDIUM** is entering the next clinical phases with its lead compounds to diagnose and treat metastatic prostate, neuroendocrine tumours and breast cancer," says **Leila Jaafar, MD, CEO and co-founder of NUCLIDIUM**. "Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care delivery and waste management, making these therapies more accessible worldwide. Our ground-breaking next generation copper theranostic platform also allows us to rapidly develop new targets across a wider range of cancers, particularly those highly relevant to women's health."*

Since August 2020, **Neva SGR** has achieved the goals it set for its first three funds — **Neva First** for global investments, **Neva First Italia** dedicated to national companies, and **Fondo Sei** for the development of Italian innovation ecosystems — investing nearly €190 million in 43 fast-growing innovative companies and distributing approximately €13 million to its investors. Furthermore, thanks to the **new funds Neva II and Neva II Italia**, launched in September 2024, it has already invested an additional €45 million in five companies.

Neva SGR

Neva SGR, venture capital arm of the Intesa Sanpaolo Group and fully owned by the Intesa Sanpaolo Innovation Center, plans and manages investment funds for professional investors interested in seizing diversification and high-yield opportunities offered by Venture Capital investments. Neva SGR can count on the Intesa Sanpaolo Innovation Center network and Intesa Sanpaolo Group's strength, financial resources, know-how and network of relationships, a unique source of value on the market. Neva SGR can watch trends and markets from a privileged position and takes action with the strength and the responsibility of Italy's leading banking group.

Neva SGR is the perfect combination of the Intesa Sanpaolo Group's strength, reputation and stability with the best practices of international venture capital firms. Neva SGR aims to contribute to the growth of the Italian economy through investments in new technologies and to be the market maker of the Venture Capital asset class in Italy.

www.nevaSGR.com

Intesa Sanpaolo

Intesa Sanpaolo, with €417 billion in loans and €1,400 billion in customer financial assets at the end of March 2025, is the largest banking group in Italy with a significant international presence. It is a European leader in wealth management, with a

strong focus on digital and fintech. In the ESG area, €115 billion of Impact disbursements are planned for the community and green transition by 2025. The programme for the benefit and support of people in need is €1.5 billion (2023-2027). The Bank's museum network, the Gallerie d'Italia, is an exhibition venue for the Bank's own artistic heritage and cultural projects of recognised value.

News: group.intesasanpaolo.com/en/newsroom

X: @intesasanpaolo

LinkedIn: linkedin.com/company/intesa-sanpaolo

Media Relations

Intesa Sanpaolo

Corporate & Investment Banking and Governance Areas

stampa@intesasanpaolo.com

www.intesasanpaolo.com/it/news

NUCLIDIUM

NUCLIDIUM is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. The company's operations in Switzerland and Germany combine innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and clinically superior theranostic solutions to patients worldwide. NUCLIDIUM is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women's health.

Investor/Media Contact NUCLIDIUM

Trophic Communications

Stephanie May

E-mail: NUCLIDIUM@trophic.eu

Phone: +49 171 1855682